{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-012103","form_type":"8-K","ticker":null,"cik":"0001260990","company_name":"Oncternal Therapeutics, Inc.","filed_at":"2023-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.213511+00:00","generated_at":"2026-06-17T04:57:06.030480+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Oncternal receives Nasdaq deficiency notice for bid price below $1.00","bullets":["Received Nasdaq deficiency letter on April 4, 2023 due to closing bid price below $1.00 for 30 consecutive business days.","Has until October 2, 2023 to regain compliance by closing at $1.00 or more for at least 10 consecutive trading days.","May consider a reverse stock split if approved by stockholders to cure the bid-price deficiency.","Stock continues trading on Nasdaq Capital Market under ONCT; no immediate delisting impact."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-012103","json":"https://secwatch.observer/filing/0000950170-23-012103.json","markdown":"https://secwatch.observer/filing/0000950170-23-012103.md","text":"https://secwatch.observer/filing/0000950170-23-012103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1260990/000095017023012103/0000950170-23-012103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1260990/000095017023012103/onct-20230404.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:57:06.030480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"faf6585dfda2e538a03b10c5b03b57f7fd9da484","claim":"Oncternal Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"April 4, 2023, Oncternal Therapeutics, Inc. (“Oncternal”) received a letter from the Nasdaq staff indicating that, for the last thirty consecutive business days, the bid price for Oncternal’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Oncternal has been provided an initial period of 180 calendar days, or until October 2, 2023, to regain compliance. The letter states that the Nasdaq staff will provide written notification that","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1260990/000095017023012103/0000950170-23-012103-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}